BrightPath Biotherapeutics Co., Ltd. (4594.T)
JPY 39.0
(0.0%)
JPY 39.0
(0.0%)
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2023 | -1.16 Billion JPY | 21.37% |
| 2022 | -1.48 Billion JPY | -0.1% |
| 2021 | -1.48 Billion JPY | 13.69% |
| 2020 | -1.71 Billion JPY | 7.44% |
| 2019 | -1.85 Billion JPY | 1.41% |
| 2018 | -1.88 Billion JPY | -19.48% |
| 2017 | -1.57 Billion JPY | -41.62% |
| 2016 | -1.11 Billion JPY | -11.99% |
| 2015 | -994.46 Million JPY | -141.12% |
| 2014 | -412.43 Million JPY | 0.0% |
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2024 Q1 | -330.42 Million JPY | -54.17% |
| 2023 Q2 | -258.16 Million JPY | 12.71% |
| 2023 Q1 | -295.75 Million JPY | -13.64% |
| 2023 Q3 | -399.84 Million JPY | -54.88% |
| 2023 FY | -1.16 Billion JPY | 21.37% |
| 2023 Q4 | -214.31 Million JPY | 46.4% |
| 2022 Q4 | -260.25 Million JPY | 37.23% |
| 2022 Q3 | -414.64 Million JPY | -58.23% |
| 2022 FY | -1.48 Billion JPY | -0.1% |
| 2022 Q2 | -262.04 Million JPY | 52.24% |
| 2022 Q1 | -548.69 Million JPY | -35.31% |
| 2021 Q3 | -354.74 Million JPY | -10.54% |
| 2021 Q1 | -402.98 Million JPY | 8.71% |
| 2021 Q4 | -405.52 Million JPY | -14.31% |
| 2021 Q2 | -320.93 Million JPY | 20.36% |
| 2021 FY | -1.48 Billion JPY | 13.69% |
| 2020 Q4 | -441.44 Million JPY | 12.35% |
| 2020 FY | -1.71 Billion JPY | 7.44% |
| 2020 Q1 | -409.93 Million JPY | 21.18% |
| 2020 Q2 | -364.63 Million JPY | 11.05% |
| 2020 Q3 | -503.62 Million JPY | -38.12% |
| 2019 Q2 | -420.25 Million JPY | -0.71% |
| 2019 Q4 | -520.06 Million JPY | -3.98% |
| 2019 Q1 | -417.29 Million JPY | -0.7% |
| 2019 Q3 | -500.16 Million JPY | -19.01% |
| 2019 FY | -1.85 Billion JPY | 1.41% |
| 2018 FY | -1.88 Billion JPY | -19.48% |
| 2018 Q4 | -414.37 Million JPY | 8.45% |
| 2018 Q3 | -452.6 Million JPY | -4.29% |
| 2018 Q2 | -433.98 Million JPY | 25.6% |
| 2018 Q1 | -583.35 Million JPY | -45.21% |
| 2017 Q1 | -263.33 Million JPY | 34.29% |
| 2017 Q2 | -423.99 Million JPY | -61.01% |
| 2017 Q3 | -488.08 Million JPY | -15.11% |
| 2017 Q4 | -401.73 Million JPY | 17.69% |
| 2017 FY | -1.57 Billion JPY | -41.62% |
| 2016 FY | -1.11 Billion JPY | -11.99% |
| 2016 Q3 | -236.05 Million JPY | 17.43% |
| 2016 Q2 | -285.9 Million JPY | -49.75% |
| 2016 Q1 | -190.92 Million JPY | 4.97% |
| 2016 Q4 | -400.77 Million JPY | -69.78% |
| 2015 FY | -994.46 Million JPY | -141.12% |
| 2015 Q4 | -200.91 Million JPY | -1.04% |
| 2015 Q3 | -198.84 Million JPY | 37.18% |
| 2015 Q1 | -278.15 Million JPY | 0.0% |
| 2015 Q2 | -316.54 Million JPY | -13.8% |
| 2014 FY | -412.43 Million JPY | 0.0% |
| Name | Net Income | Net Income Difference |
|---|---|---|
| KOHJIN BIO CO LTD | 384 Million JPY | 404.188% |
| PRISM BioLab Co.,LTD | -526.91 Million JPY | -121.684% |
| GNI Group Ltd. | 8.09 Billion JPY | 114.431% |
| Linical Co., Ltd. | 338.26 Million JPY | 445.315% |
| Trans Genic Inc. | 4.08 Million JPY | 28694.419% |
| MEDINET Co., Ltd. | -1.43 Billion JPY | 18.768% |
| Soiken Holdings Inc. | -662.2 Million JPY | -76.393% |
| Cytori Cell Research Institute, Inc. | 138.15 Million JPY | 945.487% |
| AnGes, Inc. | -7.43 Billion JPY | 84.295% |
| OncoTherapy Science, Inc. | -1.28 Billion JPY | 9.32% |
| Nxera Pharma Co., Ltd. | -7.19 Billion JPY | 83.761% |
| Immuno-Biological Laboratories Co., Ltd. | 186.69 Million JPY | 725.667% |
| NanoCarrier Co., Ltd. | -780 Million JPY | -49.754% |
| Carna Biosciences, Inc. | -1.15 Billion JPY | -1.317% |
| CanBas Co., Ltd. | -1.2 Billion JPY | 3.384% |
| D. Western Therapeutics Institute, Inc. | -812.41 Million JPY | -43.78% |
| RaQualia Pharma Inc. | -323.66 Million JPY | -260.896% |
| Chiome Bioscience Inc. | -1.22 Billion JPY | 4.257% |
| Kidswell Bio Corporation | -1.42 Billion JPY | 17.861% |
| PeptiDream Inc. | 3.03 Billion JPY | 138.477% |
| Oncolys BioPharma Inc. | -1.93 Billion JPY | 39.743% |
| Ribomic Inc. | -1.02 Billion JPY | -14.044% |
| SanBio Company Limited | -2.64 Billion JPY | 55.821% |
| Healios K.K. | -3.82 Billion JPY | 69.446% |
| Kubota Pharmaceutical Holdings Co., Ltd. | -1.48 Billion JPY | 21.584% |
| Delta-Fly Pharma, Inc. | -1.42 Billion JPY | 18.281% |
| StemRIM | -2.02 Billion JPY | 42.231% |
| CellSource Co., Ltd. | 923.14 Million JPY | 226.533% |
| FunPep Company Limited | -933.41 Million JPY | -25.141% |
| Kringle Pharma, Inc. | -854.15 Million JPY | -36.754% |
| Stella Pharma Corporation | -763.74 Million JPY | -52.941% |
| TMS Co., Ltd. | -960.04 Million JPY | -21.67% |
| Noile-Immune Biotech Inc. | -1.13 Billion JPY | -3.369% |
| Cuorips Inc. | -632.18 Million JPY | -84.77% |
| K Pharma,Inc. | 260.33 Million JPY | 548.693% |
| Takara Bio Inc. | 1.48 Billion JPY | 178.924% |
| ReproCELL Incorporated | -31.41 Million JPY | -3618.23% |
| PhoenixBio Co., Ltd. | 26.37 Million JPY | 4528.243% |
| StemCell Institute Inc. | 310.98 Million JPY | 475.612% |
| Japan Tissue Engineering Co., Ltd. | 143.16 Million JPY | 915.876% |
| CellSeed Inc. | -846.53 Million JPY | -37.984% |